Minimal residual disease in peripheral blood compared to bone marrow in patients treated for acute myeloid leukemia
- Conditions
- Acute myeloid leukemia
- Registration Number
- NL-OMON25015
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 151
Inclusion Criteria
Patient with:
- a diagnosis of AML and related precursor neoplasms according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML), or
- acute leukemia’s of ambiguous lineage according to WHO 2008 or
- a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R score > 4.5.
Treated according to HOVON clinical trials with intensive chemotherapy;
Age 18 yr or older;
A bone marrow aspiration has been scheduled;
WHO performance status 0, 1 or 2;
Written informed consent.
Exclusion Criteria
Pregnant or lactating females;
Unwilling or not capable to use effective means of birth control.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method